The new board and the team of SensoDetect have the last 4 months worked in a focused manner to detail the long-term strategy of the company as well as securing the funds and resources to realize the same. Thanks to this work and the strong evidence presented in the research from Uppsala University Hospital, “Auditory
EuroAsia patents 2108550EA has been granted. The SensoDetects main portfolio is approved in the Euroasia (Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan) area. IP portfolio strenghtens through this in especially one very important market, Russia. In these countries, there is similar problems in Psychiatry as in the rest of the world.
The technology from SensoDetect has been proven through research. A recent blind study at Uppsala University Hospital published in 2017, using SensoDetect technology concluded “The ABR profiling tests discriminated schizophrenia and ADHD versus healthy controls with high sensitivity and specificity”. For further reading, go to AktieTorget.